Results 231 to 240 of about 36,609,695 (340)

New therapeutic options for metabolic‐associated steatotic liver disease

British Journal of Clinical Pharmacology, EarlyView.
An increasing number of patients are being diagnosed with metabolic dysfunction‐associated steatotic liver disease (MASLD). MASLD results from disturbances in hepatic lipid metabolism and is associated with an increased risk of cirrhosis and hepatocellular carcinoma and significant extrahepatic morbidity, including cardiovascular disease and ...
Tessa Straatmijer, Midas Mulder
wiley   +1 more source

Type 1 diabetes mellitus induced by sintilimab: a case report and related case literature analysis. [PDF]

Front Endocrinol (Lausanne)
Su H, Zhao X, Liu H, Li M, Geng H.
europepmc   +1 more source

Hypertension in obesity: A focus on individualized pharmacotherapy and the role of body composition, on behalf of the European Society of Hypertension Working Group on Diabetes and Metabolic Risk Factors and Working Group on Lifestyle, Cardiovascular Pharmacotherapy and Adherence

British Journal of Clinical Pharmacology, EarlyView.
Hypertension in obesity represents a major global health challenge, closely linked to the global epidemics of obesity, type 2 diabetes and metabolic dysfunction. Excess adiposity contributes to elevated blood pressure through multiple, interrelated mechanisms, including activation of the renin–angiotensin–aldosterone system, sympathetic nervous system ...
Christina Antza, Andrej Belancic, Jens Jordan, Alberto Esteban, Anna Oliveras, Ryan McNally, Panagiota Anyfanti, Jorie Versmissen, María S. Fernández‐Alfonso, Vasilios Kotsis, Thomas Weber, Alexandre Persu, Reinhold Kreutz   +12 more
wiley   +1 more source

Bariatric/Metabolic Surgery in Type 1 and Type 2 Diabetes Mellitus

Eurasian Journal of Medicine, 2019
Mufide Nuran Akcay, Erdem Karadeniz, Ali Ahiskalioglu   +2 more
doaj   +1 more source

Type 1 Diabetes Mellitus Pathogenesis: Mechanisms, Early Diagnostic Strategies, and Emerging Therapeutic Approaches. [PDF]

Pathophysiology
Ngcobo NN, Sibiya NH.
europepmc   +1 more source

A British Pharmacological Society Position Statement on Medications in Pregnancy and Lactation

British Journal of Clinical Pharmacology, EarlyView.
Agnesa Mustafa, Cleodie C. Swire, Reya V. Shah, Bernadette Jenner, Rory H. McLean, Muhammad Shamsher Ahmed, Adrie Bekker, Julia Zöllner, Rachel K. Scott, Robert R. Bies, Sara K. Quinney, Dagan O. Lonsdale, Emma Forton Magavern, Catriona Waitt, Anita Banerjee   +14 more
wiley   +1 more source

Targeting neutrophil extracellular traps in metabolic and immune niche: Nanomaterials for diabetes tissue regeneration

BMEMat, EarlyView.
The effects of NETs on regeneration of various diabetic tissues, and strategies targeting NETs for diabetes tissue regeneration. In the diabetic environment, NETs undergo complex metabolic and immune reprogramming, leading to dynamic changes in antibacterial and proinflammatory functions, and affecting regeneration of multiple systemic tissues.
Xinyi Jiang, Muxin Yue, Kai Mao, Boon Chin Heng, Noor Azlin Yahya, Yunsong Liu, Zheng Li   +6 more
wiley   +1 more source

Drug‐Coated Balloon‐Based Strategy for De Novo Coronary Artery Disease Across Complex and High‐Risk Indicated Percutaneous Coronary Intervention Risk Categories: A Multicenter Registry Study

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Evidence regarding the risk‐stratified effectiveness of drug‐coated balloon (DCB)‐based PCI for de novo coronary artery disease (CAD) remains limited, particularly in patients undergoing complex and high‐risk indicated percutaneous coronary intervention (CHIP PCI).
Dong Oh Kang, Sunwon Kim, Ae‐Young Her, Eun‐Seok Shin   +3 more
wiley   +1 more source

Childhood type 1 diabetes mellitus and gut microbiota: from microbiome characteristics to prevention and treatment strategies. [PDF]

Front Cell Infect Microbiol
Yang C.
europepmc   +1 more source